This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Integrated Financial Results for the quarter ended 30th June 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts less than Nifty Microcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kerala Ayurveda Ltd reported a sharp turnaround in Q1 FY26 (quarter ended 30th June 2025) with standalone profit after tax of ₹206.71 lakhs versus a loss of ₹129.40 lakhs in the same quarter last year. Standalone revenue from operations grew modestly to ₹1,756.58 lakhs from ₹1,639.60 lakhs (~7% growth). Consolidated revenue rose to ₹2,861.16 lakhs from ₹2,741.35 lakhs, with consolidated PAT after minority interest jumping to ₹198.86 lakhs from ₹31.63 lakhs. Other income surged to ₹999.90 lakhs standalone, boosted by a one-time ₹8.04 crore gain from sale of immovable property. The statutory auditor (G. Joseph & Associates) issued an unqualified review opinion. The Board also approved a postal ballot covering director continuations, a new independent director, increase in borrowing limits, and material related party transactions with Katra Holding Pvt Ltd and Katra Phytochem (India) Pvt Ltd.
A clear profit turnaround versus last year's loss is positive for sentiment, though a meaningful chunk of the profit came from a one-time property sale rather than core operations, so underlying growth looks more modest. The proposed related party transactions and higher borrowing limits are governance points shareholders should review in the postal ballot.
| Q1 FY26 | Q1 FY25 | Change | |
|---|---|---|---|
| Revenue | ₹28.61 Cr | ₹28.64 Cr | −0.1% |
| Operating profit | −₹6.66 Cr | −₹0.01 Cr | loss widened |
| Profit after tax | ₹2.03 Cr | ₹0.46 Cr | +340.9% |
| EBITDA margin | -14.6% | 2.8% | −17.4 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.